A Phase 2 interventional study of BIO89-100 and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by 89bio, Inc.. Completed at 89 sites in 2 countries. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by 89bio, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 63rd largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 403rd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 57 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
89bio, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
89bio, Inc. has 3 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Key Inclusion Criteria:
-confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation.
Key Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BIO89-100
Drug: BIO89-100
Drug: BIO89-100
Drug: Placebo
Drug: Placebo
Drug: BIO89-100 · Drug: Placebo
Subcutaneous injection
Also known as: Pegozafermin
Subcutaneous injection
Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis
Nonalcoholic fatty liver disease activity score (NAS) was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). NASH clinical research system (CRN) fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis). Worsening of fibrosis was defined as progression of fibrosis greater than or equal to (≥) 1 stage in NASH CRN fibrosis score.
Time frame: Week 24
Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASH
Worsening of NASH was defined as increase in nonalcoholic fatty liver disease activity score (NAS) for ballooning, inflammation, or steatosis. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: Week 24
Main Study: Number of Participants With at Least a 2-Point Improvement in NAS and no Worsening of Fibrosis
NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: Week 24
Main Study: Number of Participants With NASH Resolution and Fibrosis Improvement ≥1 Stage
NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: Week 24
Main Study: Number of Participants With at Least a 2-point Improvement in NAS Score and Are Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Responders and Alanine Aminotransferase (ALT) Responders
A responder was defined as achieving ≥2 point improvement in NAS score and are MRI-PDFF responders and ALT responders at Week 24. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. MRI-PDFF responder was defined as ≥30% reduction from baseline in liver fat by MRI-PDFF. ALT responder was defined as ≥17 units/liter (U/L) or ≥30% reduction from baseline in ALT.
Time frame: Week 24
Main Study: Percent Change From Baseline in Serum Triglycerides
Time frame: Baseline, Week 24
Main Study: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-c)
Time frame: Baseline, Week 24
Main Study: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-c)
Time frame: Baseline, Week 24
Main Study: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-c)
Time frame: Baseline, Week 24
Main Study: Percent Change From Baseline in Adiponectin
Time frame: Baseline, Week 24
Main Study: Percent Change From Baseline in HbA1c (Glycated Hemoglobin)
Time frame: Baseline, Week 24
Main Study: Percent Change From Baseline in Alanine Transaminase
Time frame: Baseline, Week 12 and 24
Main Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)
Time frame: Baseline, Week 12 and 24
Main Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)
Time frame: Baseline, Week 12 and 24
Main Study: Trough Serum Concentration of Pegozafermin
Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.
Time frame: Predose at Week 12 and 24
Main and Extension Study: Percent Change From Baseline in Alanine Transaminase
Baseline was prior to dosing on Day 1 of the main study.
Time frame: Baseline, Week 48
Main and Extension Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3)
Baseline was prior to dosing on Day 1 of the main study.
Time frame: Baseline, Week 48
Main and Extension Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF)
Baseline was prior to dosing on Day 1 of the main study.
Time frame: Baseline, Week 48
Main and Extension Study: Trough Serum Concentration of Pegozafermin
Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.
Time frame: Predose at Week 48
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of IP, whether or not considered related to the IP. TEAEs were defined as AEs that started or worsened on or after the first dose of study IP up to Week 51. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect, important medical event or reaction. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline up to Week 51
| Milestone | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|---|
| Started | 21 | 73 | 57 | 71 | 0 | 0 |
| Received at least 1 dose of study drug | 21 | 72 | 57 | 69 | 0 | 0 |
| Safety analysis set | 21 | 72 | 57 | 69 | 0 | 0 |
| Pharmacokinetic (pk) analysis set | 14 | 66 | 51 | 0 | 0 | 0 |
| Mri-pdff analysis set | 14 | 61 | 49 | 57 | 0 | 0 |
| Full analysis set | 14 | 66 | 51 | 61 | 0 | 0 |
| Completed | 20 | 59 | 51 | 63 | 0 | 0 |
| Not completed | 1 | 14 | 6 | 8 | 0 | 0 |
| Withdrew: Adverse event | 1 | 6 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 3 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized in error | 0 | 1 | 0 | 2 | 0 | 0 |
| Milestone | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|---|
| Started | 20 | 56 | 50 | 0 | 42 | 19 |
| Received at least 1 dose of study drug | 20 | 56 | 48 | 0 | 42 | 19 |
| Completed | 19 | 53 | 42 | 0 | 38 | 19 |
| Not completed | 1 | 3 | 8 | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Other than specified | 1 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 | 3 | 0 | 0 | 0 |
Nonalcoholic fatty liver disease activity score (NAS) was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). NASH clinical research system (CRN) fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis). Worsening of fibrosis was defined as progression of fibrosis greater than or equal to (≥) 1 stage in NASH CRN fibrosis score.
| Participants | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis | 5 | 12 | 11 | 1 |
Worsening of NASH was defined as increase in nonalcoholic fatty liver disease activity score (NAS) for ballooning, inflammation, or steatosis. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Participants | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASH | 3 | 14 | 11 | 4 |
NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Participants | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Number of Participants With at Least a 2-Point Improvement in NAS and no Worsening of Fibrosis | 5 | 34 | 26 | 13 |
NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. Resolution of NASH was defined as the total absence of ballooning (score=0) and absent or mild inflammation (score=0 to 1). Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. NASH CRN fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Participants | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Number of Participants With NASH Resolution and Fibrosis Improvement ≥1 Stage | 2 | 7 | 8 | 0 |
A responder was defined as achieving ≥2 point improvement in NAS score and are MRI-PDFF responders and ALT responders at Week 24. NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranged from 0 to 8, with higher scores indicating worse disease severity. MRI-PDFF responder was defined as ≥30% reduction from baseline in liver fat by MRI-PDFF. ALT responder was defined as ≥17 units/liter (U/L) or ≥30% reduction from baseline in ALT.
| Participants | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Number of Participants With at Least a 2-point Improvement in NAS Score and Are Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Responders and Alanine Aminotransferase (ALT) Responders | 4 | 31 | 22 | 5 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Percent Change From Baseline in Serum Triglycerides | -5.79 ± 19.473 | -14.87 ± 54.765 | -7.79 ± 29.612 | 1.02 ± 31.425 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-c) | 20.28 ± 74.840 | -0.42 ± 35.290 | -5.64 ± 31.944 | 0.32 ± 30.811 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-c) | -3.04 ± 18.421 | -6.94 ± 21.260 | -6.95 ± 24.120 | -0.46 ± 24.081 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-c) | 4.69 ± 13.441 | 15.82 ± 20.376 | 7.31 ± 18.690 | -2.01 ± 13.592 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Percent Change From Baseline in Adiponectin | 22.73 ± 44.045 | 31.36 ± 49.215 | 26.60 ± 46.353 | -6.28 ± 23.770 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled |
|---|---|---|---|---|
| Main Study: Percent Change From Baseline in HbA1c (Glycated Hemoglobin) | -2.24 ± 13.039 | -3.74 ± 11.216 | -2.00 ± 11.742 | -0.52 ± 9.012 |
| Percent change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Only Pooled |
|---|---|---|---|---|
| Change at Week 12 | -39.68 ± 33.615 | -42.04 ± 23.044 | -35.42 ± 28.874 | -8.62 ± 35.051 |
| Change at Week 24 | -39.28 ± 31.478 | -42.73 ± 25.218 | -31.33 ± 43.053 | -0.41 ± 48.798 |
| Percent Change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Only Pooled |
|---|---|---|---|---|
| Change at Week 12 | -45.05 ± 25.857 | -57.07 ± 19.563 | -50.63 ± 21.225 | -0.53 ± 42.062 |
| Change at Week 24 | -27.92 ± 35.209 | -51.05 ± 24.065 | -42.90 ± 40.257 | -5.80 ± 47.605 |
| Percent Change | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Only Pooled |
|---|---|---|---|---|
| Change at Week 12 | -35.34 ± 26.673 | -9.51 ± 37.151 | -13.84 ± 25.420 | 10.57 ± 33.392 |
| Change at Week 24 | -17.10 ± 34.345 | -17.76 ± 28.250 | -15.22 ± 27.429 | 9.46 ± 45.403 |
Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.
| nanograms/milliliter | Main Study: Pegozafermin 15 mg QW | Main Study: Pegozafermin 30 mg QW | Main Study: Pegozafermin 44 mg Q2W |
|---|---|---|---|
| Week 12 | 197.833 ± 110.097 | 534.289 ± 375.149 | 81.699 ± 77.099 |
| Week 24 | 168.127 ± 158.749 | 691.424 ± 718.495 | 84.033 ± 77.896 |
Baseline was prior to dosing on Day 1 of the main study.
| Percent change | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|
| Main and Extension Study: Percent Change From Baseline in Alanine Transaminase | -28.51 ± 37.164 | -45.08 ± 25.068 | -38.05 ± 28.256 | -5.03 ± 43.918 | -31.71 ± 46.868 |
Baseline was prior to dosing on Day 1 of the main study.
| Percent Change | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|
| Main and Extension Study: Percent Change From Baseline in N-Terminal Type III Collagen Propeptide (Pro-C3) | -7.89 ± 21.069 | -16.82 ± 23.675 | -14.96 ± 21.342 | 1.64 ± 33.082 | -17.22 ± 23.053 |
Baseline was prior to dosing on Day 1 of the main study.
| Percent Change | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|
| Main and Extension Study: Percent Change From Baseline in Hepatic Fat Fraction By Magnetic Resonance Imaging - (MRI-PDFF) | -23.93 ± 33.557 | -48.75 ± 29.717 | -25.93 ± 50.980 | -3.15 ± 47.992 | -59.14 ± 25.807 |
Serum trough concentration (ng/mL) of pegozafermin taken from pre-dose samples.
| nanograms/milliliter | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|
| Main and Extension Study: Trough Serum Concentration of Pegozafermin | 206.54 ± 93.104 | 471.28 ± 397.691 | 111.00 ± 88.644 | 553.45 ± 651.882 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of IP, whether or not considered related to the IP. TEAEs were defined as AEs that started or worsened on or after the first dose of study IP up to Week 51. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect, important medical event or reaction. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|
| TEAEs | 21 | 63 | 46 | 42 | 17 |
| SAEs | 1 | 5 | 8 | 6 | 2 |
Collected over Baseline up to Week 51. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main and Extension Study: Pegozafermin 15 mg QW | 0/21 (0%) | 1/21 (4.8%) | 21/21 (100%) |
| Main and Extension Study: Pegozafermin 30 mg QW | 0/72 (0%) | 5/72 (6.9%) | 62/72 (86.1%) |
| Main and Extension Study: Pegozafermin 44 mg Q2W | 0/57 (0%) | 8/57 (14%) | 45/57 (78.9%) |
| Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | 0/50 (0%) | 6/50 (12%) | 41/50 (82%) |
| Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) | 0/19 (0%) | 2/19 (10.5%) | 17/19 (89.5%) |
| Event | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|
| Tibia fractureInjury, poisoning and procedural complications | 0/21 | 0/72 | 0/57 | 0/50 | 1/19 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/21 | 0/72 | 0/57 | 0/50 | 1/19 |
| Pancreatitis acuteGastrointestinal disorders | 1/21 | 0/72 | 0/57 | 0/50 | 0/19 |
| PneumoniaInfections and infestations | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| Angina pectorisCardiac disorders | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| Diastolic dysfunctionCardiac disorders | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| Myocardial infarctionCardiac disorders | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| DepressionPsychiatric disorders | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| Post-traumatic stress disorderPsychiatric disorders | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| Suicide attemptPsychiatric disorders | 0/21 | 0/72 | 0/57 | 1/50 | 0/19 |
| Event | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main and Extension Study: Placebo (Main) and Placebo (Extension) Only | Main and Extension Study: Placebo (Main) and Pegozafermin 30 mg QW (Extension) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/21 | 26/72 | 11/57 | 5/50 | 5/19 |
| DiarrhoeaGastrointestinal disorders | 5/21 | 18/72 | 9/57 | 5/50 | 2/19 |
| Injection site pruritusGeneral disorders | 0/21 | 6/72 | 3/57 | 0/50 | 4/19 |
| HeadacheNervous system disorders | 2/21 | 6/72 | 6/57 | 3/50 | 4/19 |
| COVID-19Infections and infestations | 4/21 | 14/72 | 8/57 | 9/50 | 3/19 |
| Procedural painInjury, poisoning and procedural complications | 4/21 | 0/72 | 1/57 | 2/50 | 0/19 |
| HypertensionVascular disorders | 4/21 | 2/72 | 2/57 | 0/50 | 1/19 |
| VomitingGastrointestinal disorders | 2/21 | 13/72 | 2/57 | 2/50 | 2/19 |
| Injection site erythemaGeneral disorders | 3/21 | 11/72 | 3/57 | 3/50 | 2/19 |
| Increased appetiteMetabolism and nutrition disorders | 2/21 | 11/72 | 4/57 | 2/50 | 1/19 |
Randomized analysis set included all enrolled participants who were assigned a randomization number in the study.
| Age, Continuous(years) | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled | Total |
|---|---|---|---|---|---|
| Mean | 55.0 ± 10.45 | 55.3 ± 11.15 | 55.2 ± 11.23 | 56.3 ± 9.01 | 55.6 ± 10.41 |
| Sex: Female, Male(Participants) | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled | Total |
|---|---|---|---|---|---|
| Female | 9 | 50 | 20 | 39 | 118 |
| Male | 12 | 23 | 37 | 32 | 104 |
| Ethnicity (NIH/OMB)(Participants) | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 32 | 20 | 24 | 85 |
| Not Hispanic or Latino | 12 | 41 | 37 | 47 | 137 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Main and Extension Study: Pegozafermin 15 mg QW | Main and Extension Study: Pegozafermin 30 mg QW | Main and Extension Study: Pegozafermin 44 mg Q2W | Main Study: Placebo Pooled | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 1 | 1 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 3 | 0 | 0 | 4 |
| White | 18 | 69 | 54 | 67 | 208 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in Feb 2023, 20 months.
Results were first posted in Jan 2026, 2 years 10 months after primary completion. A results delay was requested in Feb 2024.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegozafermin
Non-alcoholic Fatty Liver Disease →
89bio, Inc.